Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Lancet (London, England)|February 16, 2010
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trialMartin E Gore, Clare L Griffin, Barry Hancock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987Joaquim Bellmunt, Hans von der Maase, Graham M Mead, et al.
European Urology Focus|November 25, 2018
Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines PanelViktor Soukup, Otakar Čapoun, Daniel Cohen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2022
Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenonGargi Banerjee, Kiran Samra, Matthew E Adams, et al.
European Urology Oncology|November 11, 2023
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines OfficeJoost L Boormans, Richard Sylvester, Lynn Anson-Cartwright, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2012
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesotheliomaJaine K Blayney, Giovanni L Ceresoli, Bruno Castagneto, et al.
Clinical Medicine (London, England)|March 25, 2021
Management of traumatic brain injury (TBI): a clinical neuroscience-led pathway for the NHSLucia M Li, Michael D Dilley, Alan Carson, et al.
European Urology|May 2, 2017
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic ReviewViktor Soukup, Otakar Čapoun, Daniel Cohen, et al.
European Urology|December 27, 2021
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder CancerMathieu Roumiguié, Ashish M Kamat, Trinity J Bivalacqua, et al.
European Urology Focus|August 1, 2018
Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?Marko Babjuk, Maximilian Burger, Eva M Compérat, et al.
Pageof 9